Management of post-transplant lymphoproliferative disorders

被引：1
|
作者：
Dierickx, Daan [1 ]
Vergote, Vibeke [1 ]
机构：
[1] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium
来源：
HEMASPHERE | 2019年 / 3卷
关键词：
RECIPIENTS; INFUSIONS; PROGNOSIS;
D O I：
10.1097/HS9.0000000000000226
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Take home messages Reduction of immune suppression followed by rituximab has become the standard of care in the majority of post-transplant lymphoproliferative disorders. Currently pre-emptive therapy is only justified in allogeneic hematopoietic stem cell recipients. Adoptive immunotherapy is a very promising therapeutic modality, both in pre-emptive setting and as treatment of established Epstein-Barr virus-positive post-transplant lymphoproliferative disorder. However, use is still restricted because of labor-intensive procedure, reimbursement issues, and availability problems.
引用
收藏
页码：74 / 77
页数：4
相关论文
共 50 条
  • [31] Central nervous system post-transplant lymphoproliferative disorders
    Castellano-Sanchez, AA
    Li, S
    Scheithauer, BW
    Weir, E
    Brat, DJ
    MODERN PATHOLOGY, 2003, 16 (01) : 289A - 289A
  • [32] Post-transplant lymphoproliferative disorders presenting in the skin in renal transplant recipients
    Lloyd-Lavery, A.
    Asher, R. G.
    Turner, R.
    Espinosa, O.
    Perkins, W.
    Matin, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 147 - 148
  • [33] Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study
    Lo, Regina Cheuk-lam
    Chan, See-ching
    Chan, Kwong-leung
    Chiang, Alan Kwok-shing
    Lo, Chung-mau
    Ng, Irene Oi-lin
    JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (05) : 392 - 398
  • [34] Challenges and advances in the management of post-transplant lymphoproliferative disease
    de Sandes-Freitas, Taina Veras
    Domingues- da-Silva, Raoni de Oliveira
    Duarte, Fernando Barroso
    JORNAL BRASILEIRO DE NEFROLOGIA, 2024, 46 (04):
  • [35] Post-transplant lymphoproliferative disorder: risk factors and management
    Malyszko, Jolanta
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (07) : 1177 - 1179
  • [36] Primary central nervous system post-transplant lymphoproliferative disorders
    Suzuki, M.
    Shibata, N.
    Kohama, A.
    Akagawa, H.
    Tanabe, K.
    Sannomiya, A.
    Uchiyama, S.
    JOURNAL OF NEUROLOGY, 2010, 257 : S118 - S118
  • [37] MYC expression in pediatric and adult post-transplant lymphoproliferative disorders
    Van Ness, Michael
    Clement, Parker
    Tripp, Sheryl R.
    Glenn, Martha J.
    Raetz, Elizabeth A.
    Smith, Lauren B.
    Lim, Megan S.
    Perkins, Sherrie L.
    Miles, Rodney R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 : 77 - 77
  • [38] Interferon-α and its effects on post-transplant lymphoproliferative disorders
    Faro, A
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1998, 20 (3-4): : 425 - 436
  • [39] Post-transplant lymphoproliferative disorders with naso- and oropharyngeal manifestation
    Akbas, Ayla
    Tiede, Christina
    Lemound, Juliana
    Maecker-Kolhoff, Britta
    Kreipe, Hans
    Hussein, Kais
    TRANSPLANT INTERNATIONAL, 2015, 28 (11) : 1299 - 1307
  • [40] CD30 Expression in Post-Transplant Lymphoproliferative Disorders
    Hartley, Christopher
    Hintzke, Maria
    Vaughan, James
    Hosking, Paul
    Harrington, Alexandra
    Kroft, Steven
    Olteanu, Horatiu
    LABORATORY INVESTIGATION, 2015, 95 : 349A - 349A
12345